Thermo Fisher Scientific (NYSE:TMO) Issues Quarterly Earnings Results, Beats Expectations By $0.19 EPS

Thermo Fisher Scientific (NYSE:TMO) released its quarterly earnings results on Thursday. The medical research company reported $5.44 earnings per share for the quarter, topping the consensus estimate of $5.25 by $0.19, FiscalAI reports. The business had revenue of $11.01 billion during the quarter, compared to analysts’ expectations of $10.86 billion. Thermo Fisher Scientific had a return on equity of 16.92% and a net margin of 15.05%.The firm’s revenue for the quarter was up 6.2% compared to the same quarter last year. During the same period last year, the firm posted $5.15 EPS. Thermo Fisher Scientific updated its FY 2026 guidance to 24.640-25.120 EPS.

Here are the key takeaways from Thermo Fisher Scientific’s conference call:

• Thermo Fisher raised full‑year guidance, now targeting $47.3B–$48.1B in revenue (6%–8% reported) and $24.64–$25.12 adjusted EPS (8%–10% growth), still assuming 3%–4% organic growth.
• Completed the ~\$9 billion acquisition of Clario, which added \$30M of revenue and \$0.01 of adjusted EPS in Q1 and is expected to contribute roughly \$900M of revenue and \$0.32 of EPS to 2026 guidance.
• Delivered a strong Q1 with \$11.01B revenue (+6%), adjusted operating income of \$2.4B (+6%) and adjusted EPS of \$5.44 (+6%), while returning capital via \$3B of buybacks and a 10% dividend increase.
• Headwinds persist from tariffs, FX and potential higher inflation (company cites a placeholder for inflation risk), and Analytical Instruments faced softness (organic -2%) with a 250 bps margin decline; China and academic/government end markets remain muted.
• Company highlighted continued innovation and commercial momentum—new product launches (e.g., Glacios 3 Cryo‑TEM, TSQ Certis, Gibco CTS Compleo), AI collaborations with Nvidia/OpenAI, and share gains in clinical research and bioproduction.

Thermo Fisher Scientific Trading Down 10.3%

Shares of Thermo Fisher Scientific stock traded down $52.73 during trading on Thursday, hitting $461.25. The company’s stock had a trading volume of 2,341,620 shares, compared to its average volume of 2,271,606. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.89 and a quick ratio of 1.53. Thermo Fisher Scientific has a 52 week low of $385.46 and a 52 week high of $643.99. The stock has a market cap of $171.41 billion, a price-to-earnings ratio of 26.01, a price-to-earnings-growth ratio of 2.72 and a beta of 0.97. The stock has a 50-day moving average price of $500.69 and a two-hundred day moving average price of $550.56.

Thermo Fisher Scientific Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, April 15th. Stockholders of record on Friday, March 13th were paid a dividend of $0.47 per share. The ex-dividend date of this dividend was Friday, March 13th. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.43. This represents a $1.88 annualized dividend and a dividend yield of 0.4%. Thermo Fisher Scientific’s payout ratio is 10.60%.

Key Headlines Impacting Thermo Fisher Scientific

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Q1 results: EPS $5.44 and revenue $11.01B topped consensus (EPS and sales beats, revenue +6.2% y/y), supporting fundamentals and near-term earnings visibility. Thermo Fisher Scientific (TMO) Q1 Earnings and Revenues Top Estimates
• Positive Sentiment: Analyst support: William Blair reiterated a Buy rating citing solid core growth and potential catalysts from AI adoption and reshoring — a vote of confidence that can sustain investor interest. Thermo Fisher Scientific: Buy Rating Reiterated on Solid Core Growth and Emerging AI, Reshoring Catalysts
• Positive Sentiment: Segment performance: Growth in Laboratory Products and Biopharma Services helped offset weakness elsewhere, underpinning the beat and recurring revenue streams. Thermo Fisher posts quarterly results beat as lab products, biopharma services grow
• Neutral Sentiment: Longer-term market tailwinds: digital lab transformation (Cloud ELN) and expanding microbiology testing markets present growth opportunities but are multi-year plays. Global Cloud ELN Service Market | USA, China, India Lead | Thermo Fisher Scientific, Agilent Technologies, Dassault Systèmes Drive Digital Lab Transformation
• Neutral Sentiment: Analyst consensus: Street view remains constructive (consensus around Moderate Buy), which cushions downside but limits surprise upside absent stronger guidance. Thermo Fisher Scientific Inc. (NYSE:TMO) Given Consensus Rating of “Moderate Buy” by Analysts
• Negative Sentiment: Market reaction: shares slipped in premarket trading despite the beat, indicating profit-taking or that forward guidance/growth cadence disappointed some traders. Thermo Fisher slips in premarket despite beating Q1 forecasts
• Negative Sentiment: Product-line softness: analytical instruments and specialty diagnostics showed weakness—a risk to near-term growth if those trends persist. Thermo Fisher posts quarterly results beat as lab products, biopharma services grow

Analyst Ratings Changes

Several analysts recently weighed in on the company. Robert W. Baird set a $653.00 price target on Thermo Fisher Scientific in a report on Friday, January 30th. UBS Group reissued a “neutral” rating and set a $615.00 price target on shares of Thermo Fisher Scientific in a report on Friday, January 30th. Wells Fargo & Company set a $683.00 price objective on Thermo Fisher Scientific in a report on Friday, January 30th. TD Cowen dropped their price objective on Thermo Fisher Scientific from $696.00 to $683.00 and set a “buy” rating for the company in a report on Friday, January 30th. Finally, Wall Street Zen raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Saturday, February 28th. One analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and two have given a Hold rating to the company. According to MarketBeat, Thermo Fisher Scientific has an average rating of “Moderate Buy” and a consensus target price of $631.25.

Insider Activity

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $541.20, for a total transaction of $216,480.00. Following the transaction, the executive vice president directly owned 20,752 shares of the company’s stock, valued at approximately $11,230,982.40. The trade was a 1.89% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Marc N. Casper sold 5,000 shares of Thermo Fisher Scientific stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $512.40, for a total value of $2,562,000.00. Following the transaction, the chief executive officer directly owned 123,925 shares in the company, valued at $63,499,170. The trade was a 3.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.33% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Brighton Jones LLC lifted its stake in shares of Thermo Fisher Scientific by 28.9% in the 4th quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock valued at $2,293,000 after purchasing an additional 988 shares during the period. Revolve Wealth Partners LLC lifted its stake in shares of Thermo Fisher Scientific by 4.2% in the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock valued at $255,000 after purchasing an additional 20 shares during the period. Darwin Wealth Management LLC acquired a new position in shares of Thermo Fisher Scientific in the 2nd quarter valued at about $170,000. Raymond James Financial Inc. lifted its stake in shares of Thermo Fisher Scientific by 7.4% in the 2nd quarter. Raymond James Financial Inc. now owns 778,822 shares of the medical research company’s stock valued at $315,781,000 after purchasing an additional 53,542 shares during the period. Finally, California State Teachers Retirement System raised its stake in Thermo Fisher Scientific by 0.4% during the 2nd quarter. California State Teachers Retirement System now owns 602,031 shares of the medical research company’s stock worth $244,099,000 after buying an additional 2,262 shares during the period. 89.23% of the stock is owned by institutional investors and hedge funds.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.